Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and mini-pigs
Painless and controlled on-demand drug delivery is the ultimate goal for the management of various chronic diseases, including diabetes. To achieve this purpose, microneedle patches are gaining increased attention. While degradable microneedle (MN) arrays are widely employed, the use of non-dissolvi...
Gespeichert in:
Veröffentlicht in: | Nanoscale horizons 2022-01, Vol.7 (2), p.174-184 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Painless and controlled on-demand drug delivery is the ultimate goal for the management of various chronic diseases, including diabetes. To achieve this purpose, microneedle patches are gaining increased attention. While degradable microneedle (MN) arrays are widely employed, the use of non-dissolving MN patches remains a challenge to overcome. In this study, we demonstrate that crosslinking gelatin methacrylate with polyethylene glycol diacrylate (PEGDA) is potent for engineering non-dissolving MN arrays. Incorporation of MoS
2
nanosheets as a photothermal component into MN hydrogels results in MNs featuring on-demand release properties. An optimized MoS
2
-MN array patch formed using a hydrogel solution containing 500 μg mL
−1
of MoS
2
and photochemically crosslinked for 5 min shows required mechanical behavior under a normal compressive load to penetrate the stratum corneum of mice or pig skin and allows the delivery of macromolecular therapeutics such as insulin upon swelling. Using
ex vivo
and
in vivo
models, we show that the MoS
2
-MN patches can be used for loading and releasing insulin for therapeutic purposes. Indeed, transdermal administration of insulin loaded into MoS
2
-MN patches reduces blood glucose levels in C57BL/6 mice and mini-pigs comparably to subcutaneously injected insulin. We believe that this on-demand delivery system might alter the current insulin therapies and might be a potential approach for delivery of other proteins.
Painless and controlled on-demand drug delivery is the ultimate goal for the management of various chronic diseases, including diabetes. |
---|---|
ISSN: | 2055-6756 2055-6764 2055-6764 |
DOI: | 10.1039/d1nh00596k |